The scrip has risen 35.19% year-to-date and 49.16% in the last 12 months. Out of 28 analysts tracking the company on Bloomberg, 19 recommend buying its shares, five have a 'hold' call, and four suggest selling it.
The scrip has risen 35.19% year-to-date and 49.16% in the last 12 months. Out of 28 analysts tracking the company on Bloomberg, 19 recommend buying its shares, five have a 'hold' call, and four suggest selling it.
<iframe src="https://hindustansphere.com/embed/cluster/77a0af5db03eba0efe5dcc6c3edd34e9d79ecf70" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Aurobindo Pharma Shares Tumble 2% Despite Q1 Profit Jump, Double Digit Revenue Guidance For FY27"></iframe>
